louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05893953: Spine Angle Comparison in Adult Seating Posture With Immediate Feedback
Official title: Comparison of Spine Angle Between Immediate Feedback and Different Conditions of Normal Adult Seating Posture
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Curvatures
Feedback, Psychological
Sitting Position
Lead sponsor: Sahmyook University
Sponsor class: OTHER
First posted: 2023-06-08
Enrollment: 28
Sex: ALL
Minimum age (years): 20
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: 1. Background: In modern society, people are spending more time sitting due to the increased use of IT devices. Prolonged sitting with incorrect posture can lead to spinal deformities and an increase in spinal diseases. Common deformities include turtle neck posture, flat back, straight neck, and bent back. Misalignment of the spine is considered an important factor in causing spinal diseases, such as pain, arthritis, and degeneration. To address these issues, researchers have developed pillows and chairs that are ergonomically designed for everyday use and have been found to be effective.
2. Purpose: This study aims to investigate whether portable equipment can help individuals recognize and maintain correct sitting posture on their own.
3. Design: This study has a cross-sectional study design. Each condition is divided into three different sitting conditions. By using post-evaluation data, the intention is to compare the effects. (Condition A: sitting on a standard chair wearing an immediately feedback device, Condition B: sitting on a gym-ball, Condition C: sitting on standard chair)
4. Subject : Twenty-eight subjects were recruited as healthy students attending S University located in Nowon-gu, Seoul.
5. Result: The study found that maintaining a sitting posture immediately resulted in a statistically significant lower angle over time at the Cervicothoracic angle compared to other interventions. Similarly, a sitting posture immediately maintained a lower angle over time at the Thoracic angle compared to other sitting postures . However, the lumbar angle showed a significant increase over time.


Eligibility criteria: Inclusion Criteria:

* Healthy 20-year-olds with no visual and hearing problems and no problems with video viewing and agreeing to participate in the experiment

Exclusion Criteria:

* Those who needed treatment due to pain in the neck, chest, or back were excluded.

Those who had been diagnosed with a diagnosis that stopped studying and stopped sports activities in the past 12 months were excluded.

Primary outcomes:
measure: Cervico-thoracic angle
timeFrame: 1minute, 5minute, 10minute
measure: Thoracic angle
timeFrame: 1minute, 5minute, 10minute
measure: Lumbar angle
timeFrame: 1minute, 5minute, 10minute
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Sahmyook University
state: Nowon-gu
Study officials:
affiliation: Sahmyook University
name: Choi Jinhyung
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05211453: A Randomised Comparison of Left and Right Sided Approaches to Ablation of the Atrioventricular Junction
Official title: A Randomised Comparison of Left and Right Sided Approaches to Ablation of the Atrioventricular Junction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atrial Fibrillation
Keywords: atrial fibrillation
atrioventricular node
Lead sponsor: East Sussex Hospitals NHS Trust
Sponsor class: OTHER
First posted: 2022-01-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare right sided atrioventricular node ablation to left sided atrioventricular node ablation

Detailed description: Right-sided atrioventricular node ablation has been the initial conventional approach however up to 18.5% of patients require switching to a left sided approach or have a challenging procedure. Previous studies have found that left sided ablation is more efficacious than right-sided ablation requiring less than 5 applications of radiofrequency energy to induce atrioventricular block.

This study will compare right sided atrioventricular node ablation to left sided atrioventricular node ablation

Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years
* Referred for atrioventricular node ablation for any such indication

Exclusion Criteria:

* Stroke or transient ischaemic attack (TIA) within 6 months
* Myocardial infarction within 6 months
* Medical conditions limiting expected survival to \<1 year
* Moderate to severe aortic stenosis
* History of aortic or mitral valve replacement
* Pregnancy or breast feeding women

Primary outcomes:
measure: Comparison of total ablation time required to induce complete atrioventricular node block
timeFrame: intraoperative
Secondary outcomes:
measure: Comparison of number of RF applications required to induce complete atrioventricular node block
timeFrame: intraoperative
measure: Comparison of total procedure time between the two groups
timeFrame: intraoperative
measure: Comparison of radiation exposure between the two groups
timeFrame: intraoperative
measure: Comparison of rate of the escape rhythm after ablation in beats/min
timeFrame: intraoperative
measure: Comparison of number of patients requiring crossover to each side
timeFrame: intraoperative
measure: Comparison of adverse events / complications between each group
timeFrame: intraoperative
measure: Comparison of patient comfort of procedure
timeFrame: intraoperative
Other outcomes:
Locations:
city: Eastbourne
country: United Kingdom
facility: Eastbourne District General Hospital
state: East Sussex
Study officials:
affiliation: East Sussex Healthcare NHS
name: Rick Veasey
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01528553: Stapling Versus 8plate for Correction of Genu Valgus
Official title: Stapling Versus 8plate for Correction of Genu Valgus. A Randomised Clinical Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Deformity
Genu Valgus
Keywords: genu valgus
lower limb
paediatric
epiphysiodesis
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2012-02-08
Enrollment: 20
Sex: ALL
Minimum age (years): 8
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In children with excessive knock knees it may be necessary to use guided growth (small surgical procedure) so the child outgrows the condition before maturity. A new implant is on the market and the investigators compare this implant (8plate) with the old technique (staples) in a randomised setup.

The hypothesis is that the 8plate provides a faster correction rate and that this treatment is superior to stapling.

Detailed description: Correcting angulating deformities of the lower limb is a subject of major interest in paediatric orthopaedics. Epiphysiodesis is the technique by which unilateral bone growth is stopped. Traditionally this has been performed with staple technique. The 8-plate technique is new and advocated because it is believed to reduce the risk of premature closure of the growth plate compared to stapling. The benefit of the 8-plate technique has not yet been proven in experimental or randomised clinical studies.

Eligibility criteria: Inclusion Criteria:

* Idiopathic genu valgus
* At least one year of remaining growth

Exclusion Criteria:

* Unilateral conditions

Primary outcomes:
measure: Treatment time
timeFrame: up to 104 weeks
Secondary outcomes:
measure: Radiological correction
timeFrame: up to 104 weeks
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: Aarhus University Hospital
name: Bjarne Møller-Madsen, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Stevens PM. Guided growth for angular correction: a preliminary series using a tension band plate. J Pediatr Orthop. 2007 Apr-May;27(3):253-9. doi: 10.1097/BPO.0b013e31803433a1.
citation: Jelinek EM, Bittersohl B, Martiny F, Scharfstadt A, Krauspe R, Westhoff B. The 8-plate versus physeal stapling for temporary hemiepiphyseodesis correcting genu valgum and genu varum: a retrospective analysis of thirty five patients. Int Orthop. 2012 Mar;36(3):599-605. doi: 10.1007/s00264-011-1369-5. Epub 2011 Oct 9.
Clinical trial NCT01479751: Comparison of Methods to Facilitate Rapid Sequence Intubation
Official title: Comparison of Mg, Ketamine, Large Dose Rocuronium, and Priming on Intubating Condition in Rapid Sequence Intubation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubating Condition
Keywords: Rocuronium
magnesium
priming
ketamine
intubation
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2011-11-24
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: In this study, methods which are known for facilitating rapid sequence intubation or accelerating rocuronium (Roc)onset are compared including magnesium (Mg), ketamine pretreatment, large dose rocuronium and priming.

Detailed description: Patients are pretreated with Mg, ketamine, or priming dose Roc. Two groups do not receive pretreatment, but are given Roc 0.6 mg/kg or 0.9 mg/kg.

Eligibility criteria: Inclusion Criteria:

* age 18 - 65 years,
* ASA 1 - 2,
* patients scheduled for elective surgery under general anesthesia,
* BMI 18.5-24.9 kg/m2
* Mallampati class I-II

Exclusion Criteria:

* neuromuscular disorder,
* cardiac/hepatic/renal insufficiency,
* pregnant.
* anticipated difficult airway
* medications that influence neuromuscular transmission

Primary outcomes:
measure: Intubation score
timeFrame: participants will be followed at the time point of intubation, an expected average of 70 sec from the start of rocuronium injection.
Secondary outcomes:
measure: Roc duration
timeFrame: participants will be followed when TOF count reaches two, an expected average of 40 min.
measure: Roc onset
timeFrame: participants will be followed when TOFcount =0 within an expected average of 4 min from the start of rocuronium injection.
measure: Hemodynamic variables
timeFrame: participants will be followed at baseline, before and for 5 min after the intubation, an expected average of 8 min after the start of anesthetic induction.
measure: TOF% at intubation
timeFrame: participants will be followed at the time point of intubation, an expected average of 70 sec from the start of rocuronium injection.
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang hopital
state: Gyeonggi-Do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Mihyun Kim, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04789551: T Cell Profiling in Patients with Multiple Sclerosis
Official title: T Cell Profiling in Patients with Multiple Sclerosis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Multiple Sclerosis
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2021-03-09
Enrollment: 40
Sex: ALL
Minimum age (years): 13
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Multiple Sclerosis who present to Boston Children's Hospital will be enrolled. A group of healthy control patients who present for elective surgery at Boston Children's Hospital will also be enrolled.

Brief summary: The goal of this research study is to to learn more about the body's immune response in patients with multiple sclerosis (MS). In MS, the body's immune cells mistakenly attack an important part of the nerves of the brain and spinal cord. The immune cells responsible for attacking the nerves in MS patients is primarily the T cells. A marker was recently discovered that might specifically identify these damaging T cells from all other T cells in the body. Understanding which T cells cause the damage in MS patients and understanding more about these specific T cells may help doctors better understand how MS occurs and could possibly prevent MS in the future.


Eligibility criteria: MS Group Inclusion criteria

-diagnosis of multiple sclerosis and present to the neurology clinic for a regular checkup or are admitted to the inpatient floor with acute symptoms.

Exclusion criteria

* Have an active infection
* Take T cell modulating drugs

Control Group Inclusion criteria -scheduled for elective surgery

* without any immunological diseases. Exclusion criteria
* Have an active infection.

Primary outcomes:
measure: T cell populations
timeFrame: up to one week
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hopsital
state: Massachusetts
Study officials:
References:
Clinical trial NCT00750451: Low Molecular Weight Heparin in Recurrent Implantation Failure
Official title: Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Fertilization in Vitro
Recurrent Implantation Failure
Keywords: fertilization in vitro
assisted reproduction
recurrent implantation failure
low molecular weight heparin
heparin
luteal phase
Lead sponsor: V.K.V. American Hospital, Istanbul
Sponsor class: OTHER
First posted: 2008-09-10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Heparin is thought to play a role in the embryo implantation process beyond its anticoagulation effects. The proposed study aims to assess the effectiveness and safety of empirical administration of low molecular weight heparin in patients undergoing a new IVF treatment cycle after multiple failed attempts.


Eligibility criteria: Inclusion Criteria:

* History of at least two previously failed fresh embryo transfer cycles
* All previously failed cycles to be performed in the American Hospital of Istanbul
* Female age ≤ 38 years
* Fresh ejaculate sperms to be used for ICSI
* No hormonal, coagulation, or immunological disorders detected
* Normal uterine cavity, as assessed by diagnostic office hysteroscopy or saline infusion sonography
* Normal female and male peripheral karyotype

Primary outcomes:
measure: Ongoing pregnancy beyond the 20th gestational week rate
Secondary outcomes:
measure: Clinical pregnancy rate
measure: Embryo implantation rate
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Assisted Reproduction Unit of the American Hospital of Istanbul
Study officials:
affiliation: American Hospital of Istanbul
name: Cumhur B Urman, M.D.
role: STUDY_DIRECTOR
References:
citation: Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, Balaban B. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod. 2009 Jul;24(7):1640-7. doi: 10.1093/humrep/dep086. Epub 2009 Apr 8.
Clinical trial NCT02055651: Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil
Official title: Descriptive Observational Study of Cardiovascular Health Risk Factors in Workers of Bayer S.A. Company in São Paulo
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Occupational Health
Keywords: Worksite
Cardiovascular
Epidemiology
Risk factors
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2014-02-05
Enrollment: 361
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Bayer's employees (São Paulo, Brazil)

Brief summary: Introduction: As employees spent most part of their time at the worksite, it provides a venue to address multiple individual risk factors and promote health. The America Heart Association (AHA) defined cardiovascular health using as metrics smoking status, body mass index, physical activity, diet, total cholesterol, blood pressure and fasting blood glucose.

Objective: Evaluate Bayer employees' cardiovascular health according to the AHA definition and the acceptance to engage in lifestyle change programs.

Methods: By the time of the annual occupational safety periodic medical examination, employees will receive an email with information about the cardiovascular health screening, exams requisition (fasting blood glucose and total cholesterol) and a copy of the written informed consent. If the employee accepts to participate, after providing a written informed consent, he will be evaluated according to the AHA cardiovascular health metrics. Data will be collected at the occupational safety electronic health record. After medical evaluation, employees will receive a printed feedback with their cardiovascular health score and will be referred to indicated lifestyle change programs (healthy weight, smoking cessation, diabetes control, high blood pressure control, dyslipidemia control).

After 12 months we will evaluate the percentage of employees who accept to participate; prevalence of the cardiovascular risk factors and distribution according to the AHA classification in ideal, intermediate and poor; adherence to lifestyle change programs.


Eligibility criteria: Inclusion Criteria:

* Employees with 20 years of age or more that daily work at Bayer's site in São Paulo
* Provide written informed consent

Exclusion Criteria:

* Employees that will no longer work for Bayer in 30 days
* Employees that are retired from work during the study period

Primary outcomes:
measure: Cardiovascular health metrics on a three-point scale (poor, intermediate, ideal)
timeFrame: 1 day
Secondary outcomes:
measure: Number of participants who are suggested to participate in a lifestyle change program and show up for at least one session
timeFrame: Up to 4 weeks after cardiovascular examination
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01137851: Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
Official title: Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients Treated With Biologic Disease Modifying Antirheumatic Drug (DMARD) Therapies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2010-06-07
Enrollment: 3940
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Commercial health plan members

Brief summary: The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)


Eligibility criteria: Patients diagnosed with Rheumatoid Arthritis (RA) who newly initiated a biologic DMARD (bDMARD) during a study timeframe of 1/01/06 to 3/31/09.

Inclusion Criteria:

* 18 to 64 years of age at index date
* Diagnosis of RA during the study period (ICD-9CM 714.xx)
* Evidence of at least one biologic DMARD of interest during the study timeframe
* Continuous enrollment during the study timeframe
* Both medical and pharmacy benefits
* No evidence of a claim for a bDMARD in the 6-month pre-period

Exclusion Criteria:

* Patients are excluded if they have a diagnosis of psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis at any time during the study timeframe; have a claim for Rituxan, IV etanercept, or IV adalimumab; or have Medicare or Medicaid during the study timeframe

Primary outcomes:
measure: Effect of patient cost share on discontinuation
timeFrame: Assessed from first prescription date and followed for 1-year
Secondary outcomes:
measure: RA-related healthcare utilization and costs
timeFrame: Pre-index: 6-month period prior to the index drug date
measure: All-cause healthcare utilization and costs
timeFrame: Pre-index: 6-month period prior to the index drug date
measure: RA-related healthcare utilization and costs
timeFrame: Post-period: Index date+365 days
measure: All-cause healthcare utilization and costs
timeFrame: Post-period: Index date+365 days
Other outcomes:
Locations:
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: